Chinizarincarbonsaeure | 6416-55-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: Chinizarincarbonsaeure
• 英文别名: 1,4-Dihydroxy-anthrachinon-2-carbonsaeure；1,4-dihydroxy-9,10-dioxo-9,10-dihydro-anthracene-2-carboxylic acid；1,4-Dihydroxy-9,10-dioxo-9,10-dihydro-anthracen-2-carbonsaeure；1.4-Dioxy-anthrachinon-carbonsaeure-(2)；9,10-Dihydro-1,4-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid；Chinizarin-carbonsaeure-(2)；2-Quinizarincarboxylic acid；1,4-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid
• CAS: 6416-55-3
• 化学式: C₁₅H₈O₆
• 分子量: 284.225
• InChiKey: UPIHXGUNPJWCON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 海关编码：
  2918990090

制备方法与用途

quinizarin fascia（化合物15）是一种葡萄糖摄取抑制剂，在50 μM浓度下，其抑制率约为24.9%。

反应信息

• 作为反应物：
  描述：

  Chinizarincarbonsaeure 在 manganese(IV) oxide 、 硫酸 作用下， 生成 pseudopurpurin
  参考文献：
  名称：

  DE260765

  摘要：

  公开号：
• 作为产物：
  描述：

  1,4-dihydroxy-9,10-dioxo-9,10-dihydro-anthracene-2,3-dicarbonitrile 在 硫酸 、 硼酸 作用下， 生成 Chinizarincarbonsaeure
  参考文献：
  名称：

  Marschalk, Bulletin de la Societe Chimique de France, 1935, vol. <5> 2, p. 1809,1819

  摘要：

  DOI：

文献信息

• Anthraquinone derivatives, process for their preparation and their use as medicaments
  申请人：LILLY INDUSTRIES LIMITED

  公开号：EP0570091A1

  公开（公告）日：1993-11-18

  Pharmaceutical compounds of the formula in which R¹ and R² are each hydrogen, hydroxyl, halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, acyloxy, -O-glucoside, optionally substituted phenyl or optionally substituted phenyl-C₁₋₄ alkoxy; R³ is CO₂H, NR'SO₂R'' where R' is hydrogen or C₁₋₄ alkyl and R'' is hydroxyl, C₁₋₄ alkyl or optionally substituted phenyl, CONR'R'' where R' and R'' are each hydrogen, C₁₋₄ alkyl, acyl or optionally substituted phenyl, CONR'OR'' where R' is C₁₋₄ alkyl or optionally substituted phenyl and R'' is C₁₋₄ alkyl or benzyl, CR'R''.CR‴ (NHR'''')CO₂H where R' and R'' are each hydrogen, C₁₋₄ alkyl or optionally substituted phenyl, R‴ is hydrogen, CO₂H or -C₁₋₄ alkylene-CO₂H, and R'''' is hydrogen or acyl, CR'R''.CHR‴CO₂H where R' and R'' are each hydrogen or C₁₋₄ alkyl and R‴ is optionally substituted phenyl, CR'R''S(O)nR‴ where R' and R'' are each hydrogen or C₁₋₄ alkyl, R‴ is optionally substituted phenyl and n is 0,1 or 2, PO₃R'R'' where R' and R'' are each hydrogen, C₁₋₄ alkyl or optionally substituted phenyl, CR'R''-PO₃R‴R'''' where R', R'', R‴ and R'''' are each hydrogen, C₁₋₄ alkyl or optionally substituted phenyl, CH=CH-PO₃R'R'' where R' and R'' are each hydrogen, C₁₋₄ alkyl or optionally substituted phenyl, CH=C-PO₃R'R''    \ PO₃R‴R''''    where R', R'', R‴ and R'''' are each hydrogen, C₁₋₄ alkyl or optionally substituted phenyl, CH₂CH-PO₃R'R''    \ PO₃R‴R''''    where R', R'', R‴ and R'''' are each hydrogen, C₁₋₄ alkyl or optionally substituted phenyl, CH=CHR' where R' is -CO₂H, nitrile, tetrazolyl, optionally substituted benzimidazol-2-yl, optionally substituted N-C₁₋₄ alkyl benzimidazol-2-yl, optionally substituted oxazol-5-yl, optionally substituted thiazol-5-yl, optionally substituted isoxazol-5-yl, optionally substituted isothiazol-5-yl or optionally substituted oxadiazol-2-yl, tetrazolyl, or pyridyl, optionally substituted benzimidazol-2-yl, optionally substituted N-C₁₋₄ alkyl benzimidazol-2-yl, optionally substituted oxazol-5-yl, optionally substituted thiazol-5-yl, optionally substituted isoxazol-5-yl, optionally substituted isothiazol-5-yl or optionally substituted oxadiazol-2-yl; and R⁴ and R⁵ are each hydrogen, hydroxy, acyloxy, nitro, C₁₋₄ alkyl, C₁₋₄ alkoxy, halo, optionally substituted phenyl, -SO₃H or -NR'R'' where R' and R'' are each hydrogen or C₁₋₄ alkyl; or a pharmaceutically acceptable salt or ester thereof.

  式中的药物化合物 其中 R¹ 和 R² 分别是氢、羟基、卤代、C₁₋₄ 烷基、C₁₋₄ 烷氧基、酰氧基、-O-葡糖苷、任选取代的苯基或任选取代的苯基-C₁₋₄ 烷氧基； R³ 是 CO₂H NR'SO₂R'' 其中 R' 是氢或 C₁₋₄ 烷基，R'' 是羟基、C₁₋₄ 烷基或任选取代的苯基、 CONR'R'' 其中 R' 和 R'' 分别为氢、C₁₋₄ 烷基、酰基或任选取代的苯基、 CONR'OR'' 其中 R' 是 C₁₋₄ 烷基或任选取代的苯基，R'' 是 C₁₋₄ 烷基或苄基、 CR'R''.CR‴ (NHR'''')CO₂H 其中 R' 和 R'' 分别是氢、C₁₋₄ 烷基或任选取代的苯基，R‴ 是氢、CO₂H 或 -C₁₋₄ 烷基-CO₂H，R'''' 是氢或酰基、 CR'R''.CHR‴CO₂H 其中 R' 和 R'' 分别是氢或 C₁₋₄ 烷基，R‴ 是任选取代的苯基、 CR'R''S(O)nR‴ 其中 R' 和 R''各自为氢或 C₁₋₄烷基，R‴为任选取代的苯基，n 为 0、1 或 2、 PO₃R'R'' 其中 R' 和 R'' 分别为氢、C₁₋₄ 烷基或任选取代的苯基、 CR'R''-PO₃R‴R'''' 其中 R'、R''、R‴ 和 R'''' 分别为氢、C₁₋₄ 烷基或任选取代的苯基、 CH=CH-PO₃R'R'' 其中 R' 和 R'' 分别为氢、C₁₋₄ 烷基或任选取代的苯基、 CH=C-PO₃R'R'' \ PO₃R‴R'''' 其中 R'、R''、R‴ 和 R'''' 各为氢、C₁₋₄ 烷基或任选取代的苯基、 CH₂CH-PO₃R'R'' \ PO₃R‴R'''' 其中 R'、R''、R‴ 和 R'''' 各为氢、C₁₋₄ 烷基或任选取代的苯基、 CH=CHR' 其中 R' 是-CO₂H、腈、四唑基、任选取代的苯并咪唑-2-基、任选取代的 N-C₁₋₄ 烷基苯并咪唑-2-基、任选取代的噁唑-5-基、任选取代的噻唑-5-基、任选取代的异噁唑-5-基、任选取代的异噻唑-5-基或任选取代的噁二唑-2-基、 四唑基，或 吡啶基、任选取代的苯并咪唑-2-基、任选取代的 N-C₁₋₄ 烷基苯并咪唑-2-基、任选取代的恶唑-5-基、任选取代的噻唑-5-基、任选取代的异恶唑-5-基、任选取代的异噻唑-5-基或任选取代的噁二唑-2-基；以及 R⁴ 和 R⁵ 分别是氢、羟基、酰氧基、硝基、C₁₋₄ 烷基、C₁₋₄ 烷氧基、卤代、任选取代的苯基、-SO₃H 或-NR'R''，其中 R' 和 R'' 分别是氢或 C₁₋₄烷基； 或其药学上可接受的盐或酯。
• Online reference calibration
  申请人：ANB Sensors Limited

  公开号：US11307168B2

  公开（公告）日：2022-04-19

  An online calibration system for an electrochemical sensor. The calibration system comprises a calibration electrode coupled with a redox species, where the redox species is configured to control a pH of a reference solution local to the calibration electrode, such that when a voltammetric signal is applied to the calibration electrode the output generated from the calibration system is determined by the local environment pH. The output signal from the calibration system is used to calibrate a reference potential generated by a reference system of the electrochemical sensor to correct for drift in the reference potential when the electrochemical sensor is being used. The calibration electrode may be disposed in a reference cell of the electrochemical sensor.

  一种用于电化学传感器的在线校准系统。校准系统包括一个与氧化还原物质耦合的校准电极，其中氧化还原物质被配置为控制校准电极本地参考溶液的 pH 值，从而当伏安信号施加到校准电极时，校准系统产生的输出由本地环境 pH 值决定。校准系统的输出信号用于校准电化学传感器的参比系统产生的参比电位，以纠正电化学传感器使用时参比电位的漂移。校准电极可安装在电化学传感器的基准池中。
• DE282493
  申请人：——

  公开号：——

  公开（公告）日：——
• Accumulation in Dasuopu ice core in Qinghai-Tibet Plateau and solar activity
  作者：Keqin Duan、Ninglian Wang、Yuefang Li、Weizheng Sun

  DOI：10.1007/bf02884987

  日期：2000.6

  The time series of accumulation in recent 300 years correlated well with solar activity in Dasuopu ice core. Results of spectrum analysis on the accumulation time series of the Dasuopu ice core shows that there are some periods that coincide with the periods of solar activity. By comparing the long-time change trend of the accumulation in the Dasuopu ice core with various kinds of indexes of solar activity intensity, a negative correlation is found between the trend and solar activity.
• DE272301
  申请人：——

  公开号：——

  公开（公告）日：——